97 results about "Endocrine therapy" patented technology

The composition of the present invention is geared towards treating hyperhidrosis or any condition involving and/or promoting excessive sweating, typically involving the whole body, include hyperthyroidism or similar endocrine disorders; endocrine treatment for prostatic cancer or other types of malignant disorder; severe psychiatric disorders; obesity and menopause. The foamable composition of the present invention is suitable for treating palmar hyperhidrosis; axillary hyperhidrosis; plantar hyperhidrosis; hyperhidrosis of the trunk and/or the thighs; and facial hyperhidrosis; and any combination of them consisting of a therapeutic foamable composition including: an active agent, suitable for the treatment or prevention of hyperhidrosis.

Compositions and a method are provided for the treatment of prostate and other endocrine tumors in mammals, including humans, by administration of an antisense oligodeoxynucleotide (ODN) which is complementary to a portion of the gene encoding IGFBP-2. Using the Shionogi tumor model in vitro and in vivo, the administration of such an ODN was shown to reduce proliferation of tumor cells, and also to delay the progression to androgen independence. Thus, treatment of prostate and other hormone-regulated cancer in mammals, including humans, and delay of the progression of prostate tumors to androgen independence is accomplished by administering to the mammal a therapeutically effective amount of an antisense oligodeoxynucleotide which is complementary to a portion of the nucleic acid sequence encoding IGFBP-2 and which reduces the amount of IGFBP-2 in the treated cells.

Herein disclosed are methods that are predictive of resistance to endocrine therapy in an estrogen receptor-positive (ER-positive) breast cancer patient. An exemplary method comprises detecting the overexpression of MN/CA9 gene expression product(s) in a sample from an affected subject, wherein if MN/CA9 is overexpressed, then the subject is considered to have a greater probability of resistance to endocrine therapy, particularly tamoxifen, and a corresponding poorer prognosis if undergoing endocrine therapy, than if MN/CA9 is not overexpressed. MN/CA9 gene expression products useful in the predictive/prognostic methods include MN/CA IX, MN proteins/polypeptides, MN nucleic acids and soluble MN/CA IX antigen (s-CA IX). The methods are useful as an aid in the selection of treatment for a patient with an ER-positive breast tumor. The methods of the invention can be used, for example, to identify those patients requiring additional/alternative therapies, preferably, but not necessarily, therapies that are not affected by acidic pH. The methods also comprise the use of diagnostic/prognostic imaging to detect MN/CA IX in a patient tumor, wherein the presence of MN/CA IX in one or more tumors is indicative of probable resistance to antiestrogen therapy, particularly to tamoxifen.

Disclosed herein are topical compositions of 5-α reductase inhibitors, such as dutasteride or finasteride, or a pharmaceutically acceptable salt, ester, or derivative thereof and the use of the compositions for the treatment of hair loss secondary to endocrine therapy in patients with breast cancer (Endocrine Therapy-Induced Alopecia or ETIA), androgenetic alopecia (AGA), alopecia areata, and hirsutism. The topical composition is advantageous over the existing oral compositions of 5-α reductase inhibitors because the topical composition is safer and more effective. The topical formulation may allow for a slow release of the active ingredient dutasteride, better penetration at the therapeutically effective amount of dutasteride with an improved safety profile because it does not need to travel through the bloodstream to be efficacious, thereby minimizing the risk of systemic side effects.

There is provided compositions and methods for improving the therapeutic efficacy of various cancer treatments, for example endocrine therapy, chemotherapy or radiation therapy, by inhibiting the expression of one or more genes involved in the cellular autophagy response. The compositions include compositions comprising an siRNA directed against an Atg gene and may be used to inhibit expression of an Atg gene in a cell currently undergoing cancer therapy, or to treat, inhibit or prevent cancer in a subject in combination with a cancer therapy.

The present invention belongs to the field of traditional Chinese pharmaceutics, which relates to a traditional Chinese medicinal preparation for treating breast cancer and preparation method thereof.The present invention adopts supplementing qi, nourishing yin, regulating the thoroughfare and controlling vessels as therapeutic principle, which adopts the extracts of the following traditional Chinese medicine raw materials: radix astragali, Radix Codonopsis, bighead atractylodes rhizome, wolfberry, adenophora tetraphylla, epimedium sagittatum, Cornus officinalis, and auxiliary material to prepare a small preparation for treating breast cancer. By animal experiment and clinic trial, the results show that the preparation particles of the present invention can inhibit tumor growth and lung metastasis of tumor-bearing mice and enhance body antitumor enhance host anti-tumor immunity; the clinical studies showed that preparation particles of the present invention can obviously decrease sideeffects caused by a medicament for treating breast cancer and auxiliary treating endocrine, reduce adverse event, improve depression, and anxiety symptoms, and improve life quality of patient. The preparation of the present invention has the advantages of convenient administration, little dosage, no toxic side effect even long-term administration, and good evaluation.

Provided are methods of determining whether a subject having ER+ breast cancer is expected to benefit from treatment with combination endocrine therapy and mTOR inhibitor therapy. Also provided are methods of treating a subject having ER+ breast cancer.

The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.

Methods and compositions are provided for treating breast cancer in patients with a PI3K inhibitor, GDC-0941 in combination with an endocrine therapy agent.

The present invention includes methods for identifying patients who will be resistant to endocrine therapy during breast cancer treatment and determining patient outcome. The methods are based on identifying increased expression of PBX1, or the cistrome signature associated therewith, in breast tissue samples.

A set of small molecules ERα biomodulators that kill therapy-resistant ERα positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.

The invention discloses novel endocrine treatment phytochemicals which affect androgenic status. The method for treatment of 5-alpha-reductase responsive diseases using four novel 5-alpha-reductase inhibitor compounds; leucoanthocyanidin, glabrene, glabridin, and alpha-terpineol is disclosed. Glabridin does not interfere with normal testosterone to androgen receptor binding.

The invention provides an establishing method for a rabbit tongue carcinoma model. The method comprises the following steps: establishing rabbit tongue squamous carcinoma cell lines; inoculating the rabbit tongue squamous carcinoma cells under skin of a nude mouse and culturing the nude mouse; taking cultured nude mouse subcutaneous tumor tissue, and inoculating the subcutaneous tumor tissue on a rabbit tongue, to establish a rabbit tongue carcinoma model; based on the rabbit tongue carcinoma model, establishing a high lymph gland metastatic rabbit tongue carcinoma animal model. Establishing a tongue carcinoma animal model with high lymph gland metastatic potential completely re-represents clinical characteristics of tongue carcinoma and lymphatic metastasis biological characteristics, and provides better experimental basis for prevention and treatment of tongue carcinoma. The method can be used for sensitivity evaluation of anti-tumor chemotherapeutics, and can also be used for research of radiotherapy, endocrinotherapy, immunological therapy, molecular targeting treatment, and other new treatment means.

The present invention relates to a method for predicting the response of a patient diagnosed with breast cancer to treatment with an endocrine therapy drug, comprising the steps of: (a) measuring the binding of the estrogen receptor, obtained from a breast cancer tumor from said patient, generating a binding profile, said binding profile comprising the binding of the estrogen receptor from said patient on one or more co-regulator proteins or functional parts thereof in the presence and absence of one or more added phosphatases, (b) measuring the binding of the estrogen receptor, obtained from a breast cancer tumor from said patient, generating a binding profile, said binding profile comprising the binding of the estrogen receptor from said patient on one or more co-regulator proteins or functional parts thereof in the presence and absence of added estradiol, and, (c) predicting from said binding profiles the response of said patient to endocrine drug therapy. The present invention also relates to variant methods hereof and methods for predicting the response of a patient diagnosed with breast cancer to drug treatment and methods for individualized endocrine therapy of a patient diagnosed with an endocrine related disease. The invention also relates to arrays and kits for carrying out these methods.

The invention discloses a proteolytic targeted chimeric compound taking an oxygen bridge bicycloheptene compound as an estrogen receptor ligand as well as a preparation method and an application. Tworeasonable synthesis modes are adopted, a VHL ligand or a CRBN ligand serves as an E3 ligase ligand part, oxygen bridge bicycloheptene sulfonate or sulfonamide estrogen receptor ligands are connectedthrough alkyl side chains with different lengths, and a series of target product Protac molecules are obtained through synthesis. An action mode of the Protac molecules is different from that of an existing anti-breast cancer drug tamoxifen, and the Protac molecules are targeted estrogen down-regulators. The compound not only retains a certain estrogen receptor binding capacity, but also has goodestrogen receptor alpha down-regulation activity equivalent to that of fulvestrant, can realize event-driven targeted estrogen receptor degradation, and is expected to overcome drug resistance causedby traditional endocrine treatment of the ER positive breast cancer through the method.

The invention discloses a method for targeted inhibition of infiltration and transfer of glioma cells, which includes targeted inhibition of JAM2 (junctional adhesion molecules 2) of the glioma cells. Experiments show that cell proliferative activity of the glioma cells can be inhibited in vivo by 30% by inhibition on the JAM2 of the glioma cells, cell migration activity can be inhibited by more than 80%. The method has superb clinical application prospect, and by the method, non-specificity of existing drug therapy on glioma cell cases, the defects in surgical therapy, radiotherapy, chemotherapy and endocrine therapy are overcome, and the range of targeted therapy is widened.

Disclosed is a use of the CUEDC2 protein in the preparation of diagnostic agents for prognostic determination of the endocrinology therapy for the breast cancer patients and for the diagnosis of tumor such as breast cancer and ovarian cancer. The diagnostic agent comprises an antibody against the CUEDC2 protein, wherein the antibody is a monoclonal or polyclonal antibody against the CUEDC2 protein. Provided is a kit or a composition for prognostic determination of endocrinology therapy for the breast cancer patients and for the diagnosis of tumors such as breast cancer and ovarian cancer. The kit or composition comprises an antibody against the CUEDC2 protein. Further disclosed is a use of the CUEDC2 gene or protein in preparation of drugs for treating tumors, that is, small molecular substances and specific antibodies that specifically inhibit the expression or activity of the CUEDC2 gene\protein are used as a therapeutic agent to restore the sensitivity of drug-resistant tumors to drug treatment. The new use of the CUEDC2 protein provides a new basis for determining a dosage regimen of adjuvant therapy after surgical operation of the breast cancer patients, thereby improving the therapeutic effect of the anti-cancer drugs and alleviating the suffering and economic burden of the patients.

Methods for targeted breast cancer therapy in a subject based upon evaluating the stromal subtypes and CD146 composition in the adjacent tissue. ER+ breast cancers contain two CAF subtypes defined by CD146 expression. CD146^neg CAFs suppress ER expression in ER+ breast cancer cells, decrease tumor cell sensitivity to estrogen, switch ER proliferation dependency toward EGFR dependency and decrease tumor cell sensitivity to antiendocrine therapy. Conversely, the presence of CD146P^pos CAFs enhances ER expression in ER+ breast cancer cells and sustains ER-dependent proliferation and sensitivity to tamoxifen. Co-cultures of CD146^pos CAFs with tamoxifen-resistant breast cancer cells restores sensitivity to tamoxifen. Gene expression profiles of patient breast tumors with predominantly CD146^neg CAFs correlate with inferior clinical response to tamoxifen and worse patient outcomes. CAF composition contributes to treatment response and patient outcomes in ER+ breast cancer, and provide a target for drug development.